Common Antidepressant May Help People with Long COVID Fatigue

Topic: Health

A global clinical trial found that a widely available antidepressant called fluvoxamine can reduce fatigue and improve quality of life in adults with long COVID. The trial, led by McMaster University, included 399 adults in Brazil who had experienced ongoing fatigue for at least 90 days after a confirmed SARS-CoV-2 infection.

A new study has found that a common antidepressant may help people with long COVID fatigue. The study was conducted by researchers from Canada, Brazil, and the United States, and involved 399 adults in Brazil who had experienced ongoing fatigue for at least 90 days after a confirmed SARS-CoV-2 infection.

The researchers tested two existing medications: fluvoxamine (sold under the brand name Luvox) and metformin. They found that fluvoxamine was effective in reducing fatigue, while metformin was not. The study used a special design called an adaptive clinical trial, which allowed them to stop individual treatment groups early once the evidence became clear.

The researchers believe that fluvoxamine has potential as a treatment for long COVID fatigue because it is already widely available and well understood. They also note that more research is still needed to fully understand the effects of fluvoxamine on long COVID.

Long COVID continues to be a major global health challenge, affecting an estimated 65 million people worldwide. Despite its prevalence, there are few treatments supported by strong clinical evidence. This study provides new hope for people with long COVID fatigue, and highlights the importance of continued research into effective treatments.

Why It Matters

This study is important because it shows that a common medication may be able to help people with long COVID fatigue, which can have a significant impact on daily life. With an estimated 65 million people worldwide affected by long COVID, finding effective treatments is crucial.

Key Facts

• A global clinical trial found that fluvoxamine reduced fatigue and improved quality of life in adults with long COVID.
• The study included 399 adults in Brazil who had experienced ongoing fatigue for at least 90 days after a confirmed SARS-CoV-2 infection.
• Fluvoxamine is already widely available and well understood, making it a promising treatment option.
• More research is still needed to fully understand the effects of fluvoxamine on long COVID.
• Long COVID affects an estimated 65 million people worldwide.

Key Terms

Fluvoxamine

A widely available antidepressant medication that has been shown to reduce fatigue and improve quality of life in adults with long COVID.

Metformin

A common diabetes medication that was tested as a potential treatment for long COVID fatigue, but did not show significant benefits.

Implications

This study is important because it shows that a common medication may be able to help people with long COVID fatigue, which can have a significant impact on daily life. With an estimated 65 million people worldwide affected by long COVID, finding effective treatments is crucial.